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Abstract 
 
Standard myeloablative conditioning regimens for children with acute lymphoblastic 
leukaemia are based on total body irradiation (TBI). However, TBI causes profound short-
term and long-term side effects, provoking the necessity for alternative regimens. Treosulfan 
combines a potent immunosuppressive and antileukaemic effect with myeloablative activity 
and low toxicity profile. We retrospectively studied toxicity and outcome of 71 paediatric 
patients with ALL undergoing hematopoietic stem cell transplantation (HSCT) following 
treosulfan-based conditioning aiming to identify risk factors for treatment failure and dose 
depending outcome differences. Early regimen-related toxicity was low. No case of veno-
occlusive disease was reported. There was no association of toxicity with age or number of 
HSCT. Event free survival (EFS) of infants was significantly better compared to older 
children. Overall survival (OS) at three years was 51% and not significantly influenced by 
number of HSCT (first HSCT 54%, ≥ second HSCT 44%, p=0.71). In multivariate analysis, 
OS and EFS were significantly worse for patients transplanted without complete remission 
(p=0.04 and 0.004).  Treatment related mortality was low at 14%. We conclude that treosulfan 
based conditioning is a safe and efficiaous approach for paediatric ALL.  
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Introduction 
 As outcome with chemotherapy for children with acute lymphoblastic leukaemia (ALL) has 
remarkably improved, indications for allogeneic hematopoietic stem cell transplantation 
(HSCT) in first complete remission (CR1) are rare. (1-3) However, for high risk patients and 
after relapse, HSCT still represents an established therapy approach.(4) Fractionated total 
body irradiation (TBI) is the most common myeloablative conditioning procedure for children 
with high relapse risk ALL. (5, 6) In most transplant approaches, the current standard 
conditioning regimen for matched related or unrelated donors consists of TBI (12Gy) and 
cyclophosphamide or etoposide. (1, 5)  TBI has been proven to have an effective 
immunosuppressive and antileukaemic potential, however acute and late toxic effects are the 
major drawbacks of a potentially curative therapy. (7-11) In young patients or patients already 
treated with high irradiation doses before HSCT, TBI is often replaced by busulfan and 
cyclophosphamide (BU/CY). (5)   However, high-dose busulfan is associated with a 
substantial toxicity profile as well, in particular hepatic, pulmonary and neurotoxic side 
effects. (7, 12) To reduce these side effects, there is an urgent need for less toxic conditioning 
regimens with comparable antileukaemic, immunosuppressive and myeloablative potential. 
Although reduced-intensity conditioning (RIC) is an established concept for adult ALL, its 
efficacy has not been proven so far in childhood.(13, 14) TBI-free conditioning regimens 
based on chemotherapy alone have been explored for decades. However so far no 
combination of chemotherapeutic drugs has achieved a similar outcome. (12, 15, 16) 
Treosulfan is a prodrug of a bifunctional alkylating cytotoxic agent with low organ toxicity in 
paediatric patients, even for patients undergoing second HSCT. (17-19) Moreover, treosulfan 
targets hematopoietic stem cells effectively as well as having profound antileukaemic and 
immunosuppressive properties. (20, 21) A recent EBMT study demonstrated the efficacy and 
safety of treosulfan based regimens for children with haematological malignancies.(19) 
Here we report on a cohort of 71 children with ALL who underwent HSCT following a 
treosulfan based conditioning regimen.  
 
Patients and methods 
Patients 
In this retrospective study we evaluated 71 children and adolescents with ALL who 
underwent allogeneic HSCT between January 2005 and July 2010 in 24 international 
paediatric transplant centres from 10 countries (Germany, Italy, United Kingdom, Poland, 
Russia, Netherlands, Switzerland, Finland, Lithuania, Israel) following a treosulfan based 
conditioning regimen. This study represents a subanalysis of a large retrospective EBMT 
study on treosulfan for conditioning in children.(22) The study was conducted in accordance 
with the EBMT Guidelines for retrospective studies. 
Conditioning and transplantation 
Table 1 shows detailed patients characteristics. The majority of children were transplanted in 
>CR1 (58%), for the first time (69%), from an unrelated donor (UD, 56%) and with bone 
marrow as stem cell source (54%). Reasons why a treosulfan based conditioning regimen was 
chosen instead of TBI based were second or third HSCT, pre-transplant organ dysfunction or 
advanced disease stage, respectively. Treosulfan was combined with different 
chemotherapeutic agents, most frequently with cyclophosphamide (32%) or fludarabine and 
thiotepa (28%). The most frequent dose range for treosulfan was between 3x13 and 
3x15g/sqm (55%).  Standard dosages were used for the other chemotherapeutic agents for the 
majority of patients (total dosage cyclophosphamide 120 mg/kg , fludarabine 120-
180mg/sqm, thiotepa 8-10 mg/kg, melphalan 140 mg/sqm).   Twenty-two patients underwent 
subsequent HSCT, median time from first to second HSCT was1.5 years, from second to third 
HSCT 1.4 yesars. Regarding age, gender, donor, treosulfan dose and additional chemotherapy 
patients undergoing subsequent transplantation did not differ significantly from patients at 
first transplant. Significant differences between the two groups were stem cell source (first 
transplant: BM 53%, CB 20%, PB 27%; subsequent transplant: BM 55%, CB 0%, PB 45%, 
p=0.042) and disease status with higher proportion of patient in >CR1 at subsequent 
transplant (77% vs 49%, p=0.044) while percentage of patients without CR was similar (both 
14%). 
Most children received a CsA containing GvHD prophylaxis (83%). Acute and chronic GvHD 
were graded according to the Seattle criteria. (23) Early regimen related toxicity (RRT) until 
day +100 was defined and graded using the Short Name based on the Common Terminology 
Criteria for Adverse Events v3.0 (CTCAE), available online at: http://ctep.cancer.gov/forms/.  
Endpoints and statistics 
Outcome was measured as follows: myeloid engraftment (3 consecutive days with an absolute 
neutrophil count (ANC) >0,5x10E/L), graft failure, early RRT until day +100, cumulative 
incidence of acute (at day +100) and chronic GvHD (at 1 year), overall survival (OS), disease 
related mortality (DRM), treatment related mortality (TRM), event-free survival (EFS), 
relapse incidence, non-relapse mortality at 3 years. For all endpoints, the time to event 
interval started at the day of HSCT, and ended at the day of the respective first event for 
uncensored or at the day of last follow up for censored individuals. 
Univariate statistical analysis was done in prospectively identified subgroups defined by 
remission status, conditioning regimen, number of HSCT and patient age. Kaplan-Meier 
estimates and log-rank test were used to evaluate OS and EFS.(24, 25) For OS, deaths from 
any cause were considered an event. Relapse, progression or death from any cause were 
considered an event for EFS. Cumulative incidences of events were calculated by the method 
of Fine and Gray for censored data subject to competing risks, and compared using the Gray 
test.(26, 27) The cumulative incidence of non-relapse mortality was estimated taking into 
account the competing risk of mortality after relapse, the cumulative incidence of 
relapse/progression taking into account the competing risks of death without relapse and graft 
failure, the cumulative incidence of ANC engraftment taking into account the competing risks 
of lost graft, death without engraftment and subsequent HSCT, and the cumulative incidence 
of TRM taking into account the deaths after relapse and subsequent SCT without treosulfan-
based conditioning. Mantel-Haenszel Chi-Square test and Chi-Square test were used to 
compare categorical non time-to event variables: toxicities, acute GvHD and chronic GvHD. 
Multivariate analysis was performed to study the impact of confounding factors on the 
defined outcomes. Cox regression was used to model the time to relapse, TRM, EFS and OS, 
and logistic regression was used to model the rate of acute GvHD of grade 3/4, and the 1 year 
rate of chronic GvHD.(24, 25, 28) Because of the relatively small sample size and hence low 
GvHD numbers, treosulfan dose and patient age were included into the logistic regressions as 
continuous variables and only a possible linear relationship with the respective dependent 
variable was investigated. 
The statistical analysis was done with SAS System V9.2 (2008, SAS Institute, Cary, NC). All 
p-values below 0.05 were considered significant. 
 
Results 
Early regimen related toxicity 
Early regimen related toxicity is shown in detail in table 2. Stomatitis, diarrhea, vomiting, 
respiratory toxicity, elevated bilirubin, elevated SGOT, CNS toxicity and peripheral 
neurological (PN) toxicity ≥ grade 3 occured in 26% (18/70), 17% (12/71), 8% (6/71), 10% 
(7/70), 10% (7/69), 19% (13/69), 3% (2/70) and 3% (2/68) of patients, respectively. Grade 4 
toxicity of any kind was observed in less than 10% of patients. No patient developed veno-
occlusive disease (VOD). 
Overall, severe neurotoxicity was low (CNS and/or PN grade 3 or 4: 3/71, 4%), in particular 
no central and peripheral neurotoxicity was seen when treosulfan was combined with 
fludarabine and thiotepa. 
Toxicity was similar in all age groups (table 3). Infants did not show a significantly higher 
toxicity compared to older children except for vomiting grade 3/4 which tended to occur more 
frequently in this younger age group. 
Early RRT of any category was not higher for patients undergoing second or third HSCT 
compared to patients at first HSCT (table3). There was no significant association between 
higher treosulfan dose and grade 3 or 4 toxicity (table 3). 
Engraftment 
Myeloid engraftment was achieved in 68/70 (97%) of patients at a median of 18 days (range 
(8-84). The remainder two patients died on day +15 and +38 without signs of engraftment. 
For one patient, information on engraftment was not available in the database. 
Acute and chronic GvHD 
Acute GvHD occurred in 54% (37/69) of patients, GvHD ≥ grade 3 was observed in 16% 
(11/69). There was no significant association between acute GvHD ≥ grade 3 and treosulfan 
dose (<3x11 g/sqm 13%, 3x11-3x13 g/sqm 14%, >3x13 g/sqm 18%, p=0.817).  
Twenty-one % of patients (13/61) showed signs of chronic GvHD (extensive GvHD in 4/61, 
7%). There was a significant influence of treosulfan dose and chronic GvHD with lower 
chronic GvHD rates in patients who received higher treosulfan dose (<3x11 g/sqm 63%, 
3x11-3x13 g/sqm 15%, >3x13 g/sqm 15%, p=0.027). No patient in the fludarabine/thiotepa 
group suffered from acute GvHD grade 4 or extensive chronic GvHD.   
Acute GvHD grade 3 /4 and chronic GvHD occurred in only 4/37 (11%) and 5/34 (15%) 
patients who received bone marrow as stem cell source compared to 7/22 (32%, p=0.081) and 
5/18 (28%, p=0.287) following HSCT with peripheral blood stem cells. Occurrence of acute 
GvHD grade 3/4 or chronic GvHD was not significantly influenced by number of HSCT (first 
HSCT 21 and 10%, >first HSCT 5 and 0%, p 0.09 and 0.16, respectively). 
In a multivariate setting, we could not identify statistically significant independent risk factors 
(impact of number of HSCT, remission status, age, treosulfan dose, conditioning regimen, 
donor type and stem cell source) on the incidence of acute GvHD of grade 3/4 and chronic 
GvHD.   
Outcome 
Overall and event-free survival at 3 years for all 71 patients were 51 ± 6% and 39 ± 6%, 
respectively. There was no statistically significant difference between OS and EFS of patients 
at first HSCT and patients who underwent ≥ second HSCT (figure 1A,B). OS and EFS 
correlated significantly with remission status, with a significantly better outcome for patients 
in CR1 compared to >CR1 and no CR (figure 2A,B). 
Treatment related mortality at 2 years was low for the whole group (14± 4%) and particularly 
low in patients undergoing HSCT in CR (CR1 10 ±7%, >CR1 12±5%), while patients not in 
CR at HSCT showed a tendency for higher TRM (30±14%, p=0.28, figure 2C). Main cause 
for death was disease related (32±6%), relapse incidence at 3 years being 47±6% (n=34). 
DRM was high in patients who underwent HSCT without having reached CR (figure 2D).   
Infants had a better OS compared to older children, regarding EFS this difference was 
statistically significant (figure 1C, D). No infant died of treatment related toxicity (0.5-1 year 
0%, 1-12 years 17±6%, >12 years 14±7%, p=0.45).  
EFS tended to be worse in the low dose group of treosulfan, however this difference was not 
significant (<3x11 g/sqm 25 ± 15%, 3x11-3x13 g/sqm 47±11%, >3x13 g/sqm 38± 8%, 
p=0.51). 
Regarding the different combinations of conditioning drugs, OS, EFS, TRM, DRM and 
relapse incidence were not significantly different between the various conditioning regimens. 
Multivariate analysis 
In a Cox regression analysis of EFS, OS, TRM and relapse, the following risk factors were 
included: number of HSCT, remission status, age, treosulfan dose, conditioning regimen, 
donor type and stem cell source (table 4).  
Undergoing HSCT without having achieved CR was associated with worse OS (p=0.041) and 
EFS (p=0.008). Despite a very small group of 6 patients with other combinations of 
conditioning drugs associated with worse outcome, OS, EFS and the incidence of relapse 
were not significantly influenced by the other parameters. All statistical calculations in the 
multivariate setting have to be regarded with caution because of the relatively small number 
of patients and events. 
 
Discussion 
More than 30 years after the first successful allogeneic HSCT, TBI regimens are still the most 
common conditioning regimen for children with ALL despite the association with significant 
acute and late toxic side effects. (1, 5, 29)  The only available myeloablative alternative for a 
long time period, busulfan containing  conditioning, harbours a substantial risk of 
hepatotoxicity, veno-occlusive disease, neurotoxicity and pulmonary injury associated with 
possible high TRM. (12, 15, 30, 31) In contrast to adult ALL, the concept of reduced intensity 
conditioning could not prove similar efficacy so far.(32, 33) This situation leads to an urgent 
requirement for less toxic conditioning regimens. Although in non-malignant diseases, 
progress was reported with iv BU and therapeutic drug monitoring (TDM), it has not been 
proven so far, whether such procedures can ameliorate toxicity in children with ALL.(34, 35) 
In vivo human ALL mouse models showed a significant antileukaemic activity of treosulfan 
comparable to busulfan and cyclophosphamide, while in vitro studies even demonstrated a 
superior activity of treosulfan compared to busulfan.(20, 36) In contrast, treosulfan results in a 
lower nonhaematological toxicity with the additional advantage of linear pharmacokinetics 
without the necessity to measure blood levels as with busulfan. (17, 18) Treosulfan based 
conditioning has been applied in adult patients with haematological malignancies with 
promising results and notably low toxicity.(37-40) Few studies so far have investigated 
treosulfan as part of the conditioning regimen in paediatric patients. (19, 41-43) In a 
retrospective EBMT study, we now evaluated the toxicity profile and outcome of 71 ALL 
patients undergoing HSCT following treosulfan based conditioning. The primary aim in these 
patients was to reduce the risk of severe acute organ toxicity due to either pre-existing organ 
dysfunctions or second transplantation. To our knowledge, this is the largest study to date 
investigating treosulfan use in paediatric ALL patients. We observed a high engraftment rate 
of 97% comparable to earlier studies using treosulfan. (19, 43, 44) Early regimen related 
toxicity in the whole group was impressingly low. In particular severe toxicity (≥ grade 3) 
occurred in < 20% and consisted mainly of stomatitis and elevated liver enzymes (table 2). 
There was no significant association between higher treosulfan dose and grade 3/4 toxicity. 
Direct comparison with studies using TBI and busulfan based conditioning is difficult, 
especially when different toxicity grading scales were used. (7) High grade mucosal toxicity 
was seen in up to 45% of paediatric patients following TBI or busulfan/cyclophosphamide (7) 
and 43% in a recent paediatric study using a combination of busulfan with fludarabine(45) – 
this percentage is higher than in our cohort following treosulfan (26%). A higher rate of high 
grade mucositis following standard myeloablative conditioning (either TBI or busulfan based) 
compared to treosulfan has been reported in adult patients with haematological malignancies 
as well. (37, 46)  
Hepatic toxicity in our study was low; in particular, we did not observe a single case of VOD 
confirming a low rate of VOD in earlier treosulfan studies. (42-44, 47) Recent myeloablative 
busulfan containing regimens were reported to be associated with higher VOD rates 
especially when melphalan was added as a third drug.(34, 35, 48, 49) VOD rates following a 
conditioning with busulfan and fludarabine combined with TDM of busulfan showed 
promising lower rates of VOD, however this regimen has not been  evaluated in a  large 
cohort of paediatric ALL patients. (45, 50) In addition, the pulmonary toxicity profile of 
treosulfan based regimens was low (grade 3/4: 4% and 10%) compared to TBI and busulfan 
based regimens with deaths due to pulmonary toxicity in up to 14% of patients. (11) This 
observation is impressive as high-risk ALL patients are prone to develop either toxic or 
infectious lung complications.  
Treatment related mortality at 2 years in our cohort was 14% compared to up to 35% for 
paediatric patients following TBI-based and between 17 and 23% for busulfan based 
myeloablative conditioning.(11, 12, 48) TDM might contribute to lower TRM after busulfan 
exposure. However, a recent study on paediatric patients reported TRM of up to 27% with 
TDM.(35) As our cohort contains a high number of patients with > first HSCT (31%) and 
considerable number of patients with pre-existing organ dysfunctions, our observed low TRM 
rate is remarkable. (51) 
Infant patients undergoing HSCT are especially vulnerable for short and long term toxic side 
effects of the conditioning regimen, in particular TBI.(29, 52) (42) Hence, most groups 
currently employ chemotherapy- only conditioning regimens for children under 2-3 years, 
most frequently a backbone of busulfan and cyclophosphamide combined with melphalan 
(BuCyMel) (1, 49) However, this combination has substantial long-term and short-term toxic 
side effects in infant patients and relapse is still an unsolved problem. (52-54) Due to high 
treatment related mortality, the Interfant-06 study recently replaced  BuCyMel with either 
busulfan or treosulfan combined with fludarabine and thiotepa. Treosulfan based reduced 
intensity conditioning has been shown to be well tolerated in infants with immunodeficiency 
disorders and seems to provide sufficient antineoplastic activity in infant ALL. (41, 42, 55) 
Our data also show low short-term toxicity in infants receiving treosulfan based 
myeloablative conditioning without a single case of treatment related death. Toxicity did not 
significantly differ from older children (table 3). In addition, outcome in infants was at least 
comparable to older age groups. Regarding EFS infants even showed significantly better 
survival, although statistical calculations have to be regarded with caution as the group of 
infants was small.  Prospective studies are needed to confirm lower long term side effects in 
infants receiving treosulfan compared to TBI or busulfan.  
Our study has the limitations of being a registry-based retrospective study, hence we did not 
have sufficient data on the phenotypes of leukaemia, pre-transplant performance scores and 
information on the condition regimen of the first transplantation. Nevertheless, our cohort in 
general and specifically patients undergoing subsequent HSCT exhibited low toxicity. In our 
multivariate analysis, subsequent HSCT in comparison to first HSCT did not significantly 
influence EFS, TRM or relapse incidence. Hence, treosulfan based conditioning seems to be 
an adequate and promising option for patients undergoing subsequent HSCT. In addition, 
toxicity and outcome in an unselected ALL cohort at first HSCT is likely to be even lower 
than our reported results. Hilgendorf et al. reported before that adult patients undergoing 
HSCT for myelodysplastic syndrome with increased risk for side effects due to comorbidities 
showed lower TRM and better survival following treosulfan compared to TBI. (37)   
 
Severe acute GvHD grade 3 or 4 was observed in 16% of patients comparable to earlier 
paediatric treosulfan studies, as well as TBI or busulfan based regimens.  (7, 19, 43)  
 
Outcome for the whole group was acceptable with OS and EFS of 51 and 39%, respectively. 
As expected, outcome correlated with disease status at transplant with high significance as 
previous studies have shown for HSCT following TBI or busulfan as well.  Regarding our 
cohort, patients in CR1 had significantly better OS and EFS compared to patients in ≥CR2 
(70% vs. 52% and 70% vs 41%). This difference was also seen in paediatric patients 
following TBI conditioning: EFS for patients in CR1 was 83% compared to 47% in 
≥CR2.(15) Not surprisingly, patients undergoing HSCT without having reached CR had an 
extremely poor outcome with high DRM, high TRM and low EFS (40 and 30% at two years, 
EFS 10 ± 9%, figure 2) comparable to earlier reports following treosulfan. (43, 56). It seems 
that outcome is more dependent on disease state than on number of transplant:  Disease-free 
survival was reported as 17% for pediatric ALL patients who underwent first HSCT after TBI 
without having reached CR while according to another study overall survival was 15.3% for 
patients in Non-CR undergoing second transplant following TBI or busulfan-based 
myeloablative conditioning.(48, 57) This outcome is comparable to our patient cohort at first 
HSCT (EFS 14±13%). Our data and that of previous studies underlie the need to reduce 
leukaemia burden before HSCT. 
In patients with thalassemia, the combination of treosulfan with fludarabin and thiotepa was 
shown to be safe and efficious.(44) In our cohort, this combination was associated with a 
good outcome (OS 50%), low toxicity, low TRM (10%) and low rate of severe acute GvHD 
(15%). As thiotepa crosses the blood-brain barrier, this combination should have beneficial 
effects in preventing leukemic CNS relapse following HSCT as well. (58)  
 
This retrospective analysis serves as a basis for prospective study questions. The international 
ALL SCTped 2012 FORUM protocol (EudraCT number 2012-003032-22) compares outcome 
and toxicity of treosulfan- or busulfan-containing regimen versus TBI based conditioning in a 
prospective randomized study and has recently recruited the first patients. 
 
Summary: 
Treosulfan based conditioning is a safe approach for paediatric ALL patients undergoing 
HSCT allowing sufficient and early engraftment with efficacy in high relapse risk and 
advanced ALL. Treosulfan is associated with low toxicity, even in high risk patients as infants 
or patients undergoing subsequent HSCT. 
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Figure legends 
 
Figure 1. Overall (A) and event-free survival (B) were not significantly different between 
patients undergoing first or subsequent stem cell transplantation. Infant patients tended to 
have a better overall survival (C) while event-free survival was significantly better for this age 
group (D).  
 
Figure 2. Remission status at transplant had a significant influence on outcome: Overall (A) 
and event-free survival (B) were significantly better for patients in first complete remission. 
Patients who underwent transplant without having reached remission showed a higher 
tendency for treatment- (C) and disease-related mortality (D).  
Table 1 Patient and HSCT procedure characteristics
Number of patients 71
Age Median 9.1 years (0.8-17.9); <1 year, n= 7 (10%)
Sex Female, n= 30 (42%); male, = 41 (58%)
Disease state CR1, n= 20 (28%); >CR1, n= 41 (58%); no CR, n= 10 (14%)
Number of HSCT 1st, n= 49 (69%); >1st, n= 22 (31%)
Donor type MFD, n= 24 (34%); MMFD, n= 7 (10%); UD, n= 40 (56%)
Stem cell source BM, n= 38 (54%); PB, n= 23 (32%); CB, n= 10 (14%)
Preparative regimen according to treosulfan dose (g/sqm)
Treosulfan <3x9 n=3 (4%); +CY, 2; +FLU, 1
Treosulfan 3x9-<3x11 n= 5 (7%); +CY, 1; +FLU, 3; +other, 1
Treosulfan 3x11-<3x13 n=21 (30%); +CY, 13; +FLU, 2; +FLU/MEL, 3; +FLU/Thio, 2; +other, 1
Treosulfan 3x13-3x15 n=39 (55%); +CY, 7; +FLU, 8; +FLU/MEL, 2; +FLU/Thio, 18; +other, 4
Treosulfan >3x15 n=3 (4%); +FLU, 3
GvHD prophylaxis CsA w/o MTX/MMF ± other, n=28 (40%) 
CsA + MTX w/o MMF ± other,n=30 (42%)
CsA + MMF w/o MTX ± other, n=1 (1%)
other combinations, n=12 (17%)
Abbreviations: HSCT=hematopoietic stem cell transplantation; CR= complete remission;
MFD= matched family donor; MMFD= mismatched family donor; UD= unrelated donor 
BM= bone marrow; PB= peripheral blood; CB= cord blood; CY=cyclophosphamide;
FLU= fludarabine; MEL= melphalan; Thio= thiotepa; CsA= ciclosporin A; MTX= methotrexate; 
MMF= mycophenolate mofetil
Table 2 Early regimen related toxicity
All + FLU/Thio All + FLU/Thio All + FLU/Thio All + FLU/Thio All + FLU/Thio
Stomatitis (%) 22/70 (31) 5/20 (25) 22/70 (31) 8/20 (40) 8/70 (11) 3/20 (15) 13/70 (19) 3/20 (15) 5/70 (7) 1/20 (5)
Diarrhea (%) 17/71 (24) 6/20 (30) 29/71 (41) 7/20 (35) 13/71 (18) 4/20 (20) 6/71 (8) 2/20 (10) 6/71 (8) 1/20 (5)
Vomiting (%) 23/71 (32) 9/20 (45) 14/71 (20) 4/20 (20) 28/71 (39) 7/20 (35) 2/71 (3) 0/20 (0) 4/71 (6) 0/20 (0)
Respiratory (%) 51/70 (72) 14/20 (70) 2/70 (3) 0/20 (0) 10/70 (14) 2/20 (19) 2/70 (3) 1/20 (5) 5/70 (7) 3/20 (15)
Bilirubin (%) 40/69 (58) 10/18 (56) 13/69 (20) 4/18 (22) 9/69 (13) 4/18 (22) 5/69 (7) 0/18 (0) 2/69 (3) 0/18 (0)
SGOT (%) 16/69 (23) 6/18 (33) 28/69 (41) 8/18 (44) 12/69 (17) 2/18 (11) 12/69 (17) 2/18 (11) 1/69 (1) 0/18 (0)
VOD (%) 68/68 (100) 19/19 (100)
CNS (%) 65/70 (93) 19/19 (100) 1/70 (1) 0/19 (0) 2/70 (3) 0/19 (0) 0/70 (0) 0/19 (0) 2/70 (3) 0/19 (0)
PN (%) 65/68 (96) 19/19 (100) 1/68 (1) 0/19 (0) 0/68 (0) 0/19 (0) 1/68 (1) 0/19 (0) 1/68 (1) 0/19 (0)
Abbreviations: VOD= veno-occlusive disease; CNS= central nervous system; PN= peripheral neuropathy
Grade 4Grade 0 Grade 1 Grade 2 Grade3
Table 3 Early regimen related toxicity in correlation with treosulfan dose, age and number of HSCT
Toxicity ≥ grade 3 (%) <3*11 3*11-3*13 >3*13 p first > first p 0-1 1-12 >12 p
Stomatitis 0/7 (0) 9/21 (43) 9/42 (21) 1.00 12/48 (25) 6/22 (27) 0.84 0/6 (0) 10/42 (24) 8/22 (36) 0.18
Diarrhea 2/8 (25) 2/21 (10) 8/42 (19) 1.00 9/49 (18) 3/22 (14) 0.62 2/7 (29) 7/42 (17) 3/22 (14) 0.66
Vomiting 1/8 (13) 4/21 (19) 1/42 (2) 1.00 5/49 (10) 1/22 (5) 0.43 2/7 (29) 3/42 (7) 1/22 (5) 0.12
Max. gastrointestinal 
toxicity 2/8 (25) 10/21 (48) 14/42 (33) 1.00 19/49 (39) 7/22 (32) 0.57 3/7 (43) 14/42 (33) 9/22 (41) 0.78
Respiratory 0/8 (0) 2/20 (10) 5/42 (12) 0.42 5/48 (10) 2/22 (9) 0.86 0/7 (0) 4/41 (10) 3/22 (14) 0.58
Bilirubin 1/8 (13) 1/21 (5) 5/40 (13) 0.79 5/48 (10) 2/21 (10) 0.91 0/7 (0) 3/40 (8) 4/22 (18) 0.27
SGOT 1/8 (13) 4/21 (19) 8/40 (20) 0.83 10/48 (21) 3/21 (14) 0.52 1/7 (14) 6/42 (15) 6/22 (27) 0.47
VOD 0/8 (0) 0/21 (0) 0/39 (0)
Max. liver toxicity 1/8 (13) 5/21 (24) 11/40 (28) 0.44 13/48 (27) 4/21 (19) 0.48 1/7 (14) 8/40 (20) 8/22 (36) 0.29
CNS 0/8 (0) 1/21 (5) 1/41 (2) 1.00 2/49 (4) 0/21 (0) 0.35 0/7 (0) 1/41 (2) 1/22 (5) 0.80
PN 0/8 (0) 1/19 (5) 1/41 (2) 1.00 1/47 (2) 1/21 (5) 0.55 0/7 (0) 0/39 (0) 2/22 (9) 0.12
Max. neurological 
toxicity 0/8 (0) 1/21 (5) 2/41 (5) 0.72 2/49 (4) 1/21 (5) 0.90 0/7 (0) 1/41 (2) 2/22 (9) 0.39
Abbreviations: max= maximal, SGOT=serum glutamyl oxaloacetic transaminase, VOD= venoocclusive disease, CNS= central nervous system,   
PN= peripheral neurological
number of HSCT age at HSCT (years)Treosulfan dose (g/sqm)
Table 4 Multivariate analysis 
p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI
Number of HSCT
> 1st HSCT vs. 1st HSCT 0.87 1.1 0.5 - 2.4 0.85 0.9 0.5 - 1.9 0.82 0.8 0.2 - 4.1 0.97 1.0 0.5 - 2.3
Status (vs. CR1) 0.04 0.008 0.16 0.06
> CR1 0.59 1.4 0.4 - 4.1 0.19 2.0 0.7 - 5.3 0.83 1.2 0.2 - 8.2 0.34 1.8 0.5 - 5.9
no CR 0.04 4.4 1.1 - 18.3 0.004 6.5 1.8 - 23.5 0.13 7.0 0.6 - 88.7 0.03 5.3 1.2 - 23.9
Age (vs. 1-12 years) 0.12 0.13 0.87 0.18
0.5-1 year 0.26 0.3 0.0 - 2.7 0.23 0.2 0.0 - 2.4 0.997 NA NA 0.20 0.2 0.0 - 2.3
> 12 years 0.05 0.4 0.1 - 1.0 0.07 0.5 0.2 - 1.1 0.60 0.6 0.1 - 3.4 0.12 0.4 0.2 - 1.2
Treosulfan-Dose (vs. > 
3*13 g/sqm) 0.62 0.67 0.70 0.21
3*11-3*13 g/sqm 0.38 0.7 0.3 - 1.7 0.63 0.8 0.4 - 1.9 0.40 0.5 0.1 - 2.7 0.77 0.9 0.3 - 2.4
<3*11 g/sqm 0.82 1.1 0.4 - 3.6 0.53 1.4 0.5 - 4.3 0.996 0.0 0.0 0.12 2.7 0.8 - 9.4
Conditioning:  (vs. + 
Fludarabine+Thiotepa) 0.03 0.15 0.36 0.68
Cyclophosphamide± 0.41 1.7 0.5 - 5.9 0.39 1.6 0.5 - 4.8 0.26 4.1 0.4 - 45.7 0.85 1.1 0.3 - 4-0
Fludarabine 0.94 1.0 0.4 - 2.9 0.73 1.2 0.5 - 2.8 0.55 1.9 0.2 - 15.8 0.81 1.1 0.4 - 3.1
other 0.007 4.6 1.5 - 14.1 0.03 2.9 1.1 - 7.9 0.08 5.7 0.8 - 38.5 0.26 2.1 0.6 - 7.4
Donor (vs. other)
MSD 0.998 1.0 0.4 - 2.6 0.91 1.0 0.5 - 2.4 0.25 0.3 0.0 - 2.2 0.53 1.4 0.5 - 3.6
Stem cell source (vs. pB) 0.43 0.44 0.986 0.23
BM 0.41 0.7 0.3 - 1.7 0.48 0.7 0.3 - 1.7 0.87 0.9 0.2 - 3.7 0.73 0.8 0.3 - 2.5
CB 0.23 0.4 0.1 - 1.9 0.21 0.4 0.1 - 1.7 0.996 NA NA 0.66 0.7 0.1 - 3.4
Abbreviations: HR= hazard ratio, CI= confidence interval, HSCT= hematopoietic stem cell transplantation, CR= complete remission, vs= versus,   
TRM Relapse
MSD= sibling donor, pB= peripheral blood, BM= bone marrow, CB= cord blood 
OS EFS
 
 
